Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
75
-
Total 13F shares, excl. options
-
26.2M
-
Shares change
-
+2.18M
-
Total reported value, excl. options
-
$546M
-
Value change
-
+$45.4M
-
Put/Call ratio
-
0.52
-
Number of buys
-
33
-
Number of sells
-
-35
-
Price
-
$20.80
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2017
88 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2017.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 75 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.2M shares
of 105M outstanding shares and own 25.08% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4.59M shares), JPMORGAN CHASE & CO (3.46M shares), FRANKLIN RESOURCES INC (2.98M shares), WELLINGTON MANAGEMENT GROUP LLP (2.09M shares), BlackRock Inc. (2.05M shares), ArrowMark Colorado Holdings LLC (1.93M shares), Bank of New York Mellon Corp (1.82M shares), Polar Capital LLP (1.3M shares), VANGUARD GROUP INC (868K shares), and CANADA PENSION PLAN INVESTMENT BOARD (583K shares).
This table shows the top 75 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.